SCHEMBL2768346

SCHEMBL2768346

COc1cc(F)c(N2CCN(S(=O)(=O)c3ccc(Cl)cc3)CC2)cc1F

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 0.60
SMN1; SMN2 Q16637 4/20 0.60
HTT P42858 3/20 0.60
ALDH1A1 P00352 3/20 0.58
POLB P06746 2/20 0.58
MAPT P10636 2/20 0.54
GFER P55789 2/20 0.52
GAA P10253 2/20 0.52
TP53 P04637 3/20 0.52
TSHR P16473 4/20 0.52
HSD17B10 Q99714 2/20 0.52
USP2 O75604 2/20 0.51
MAPK1 P28482 2/20 0.51
GLA P06280 1/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
PKM P14618 1/20 0.50
ATM Q13315 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.49
NPSR1 Q6W5P4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2769068 0.90 ALDH1A1 (0.71) LMNASMN1; SMN2HTTALDH1A1POLB
SCHEMBL2767708 0.83 L3MBTL1 (0.53) LMNASMN1; SMN2HTTALDH1A1POLB
SCHEMBL2766706 0.81 LMNA (0.52) LMNASMN1; SMN2HTTALDH1A1POLB
SCHEMBL5255516 0.80 GAA (0.80) LMNASMN1; SMN2HTTALDH1A1POLB
SCHEMBL4948991 0.80 PKM (0.59) LMNASMN1; SMN2HTTALDH1A1POLB
SCHEMBL2765897 0.77 NPSR1 (0.51) LMNASMN1; SMN2HTTALDH1A1POLB
SCHEMBL23144453 0.73 ALDH1A1 (0.73) LMNASMN1; SMN2HTTALDH1A1POLB
SCHEMBL29811463 0.73 ALDH1A1 (0.73) LMNASMN1; SMN2HTTALDH1A1POLB
SCHEMBL4580893 0.72 ATM (0.81) LMNASMN1; SMN2HTTALDH1A1POLB
SCHEMBL10355428 0.72 ATM (0.81) LMNASMN1; SMN2HTTALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1627871-B1 CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE ASKA PHARM CO LTD (JP) 2010-04-14 EP disclosed
US-7449466-B2 Cyclic aminophenyl sulfamate derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2008-11-11 US disclosed
US-20060189625-A1 Cyclic aminophenyl sulfamate derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2006-08-24 US disclosed
EP-1627871-A1 CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE Teikoku Hormone Mfg. Co., Ltd. (JP) 2006-02-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189625-A1 Cyclic aminophenyl sulfamate derivative SHBG, STS, ARSA LMNA 3963/4885SMN1; SMN2 3508/4885HTT 3088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.